整合素和雄激素在乳腺癌中的作用。
Integrins and Actions of Androgen in Breast Cancer.
发表日期：2023 Aug 22
作者：
Chung-Che Tsai, Yu-Chen S H Yang, Yi-Fong Chen, Lin-Yi Huang, Yung-Ning Yang, Sheng-Yang Lee, Wen-Long Wang, Hsin-Lun Lee, Jacqueline Whang-Peng, Hung-Yun Lin, Kuan Wang
来源：
Cell Death & Disease
摘要：
雄激素已被证实能调控男性生理活动和癌症增殖。它被用来拮抗雌激素在乳腺癌细胞中引起的增殖效应。然而，证据表明，雄激素可以通过不同类型的受体和不同机制刺激雌激素受体（ER）阳性和ER阴性乳腺癌细胞的生长。雄激素诱导的癌细胞生长和转移与不同类型的整合素有关。整合素αvβ3主要在癌细胞和快速分裂的内皮细胞中表达和活化。程序性死亡配体1（PD-L1）在癌症生长中也起到重要作用。雄激素与整合素在癌细胞中的作用机制尚未完全理解。为了阐明雄激素与整合素αvβ3之间的相互作用，我们进行了分子建模以解释雄激素与整合素αvβ3的潜在相互作用。此外，我们还探讨了雄激素对PD-L1的调节机制及其影响。
Androgen has been shown to regulate male physiological activities and cancer proliferation. It is used to antagonize estrogen-induced proliferative effects in breast cancer cells. However, evidence indicates that androgen can stimulate cancer cell growth in estrogen receptor (ER)-positive and ER-negative breast cancer cells via different types of receptors and different mechanisms. Androgen-induced cancer growth and metastasis link with different types of integrins. Integrin αvβ3 is predominantly expressed and activated in cancer cells and rapidly dividing endothelial cells. Programmed death-ligand 1 (PD-L1) also plays a vital role in cancer growth. The part of integrins in action with androgen in cancer cells is not fully mechanically understood. To clarify the interactions between androgen and integrin αvβ3, we carried out molecular modeling to explain the potential interactions of androgen with integrin αvβ3. The androgen-regulated mechanisms on PD-L1 and its effects were also addressed.